UroGen Pharma Short Interest Ratio and Short Volume

Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 2,370,000 shares of URGN short. 12.47% of UroGen Pharma's shares are currently sold short. View details.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. UroGen Pharma currently has a short interest ratio of 12.0.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.47% of UroGen Pharma's floating shares are currently sold short.

UroGen Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,370,000 shares, an increase of 1.7% from the previous total of 2,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

UroGen Pharma currently has issued a total of 20,897,000 shares. Some of UroGen Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. UroGen Pharma currently has a public float of 19,010,000 shares.

12.47% of UroGen Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to UroGen Pharma: Prelude Therapeutics Incorporated (4.12%), Zealand Pharma A/S (0.00%), Kronos Bio, Inc. (11.69%), Y-mAbs Therapeutics, Inc. (10.79%), Zymeworks Inc. (0.00%), COMPASS Pathways plc (5.20%), ImmunoGen, Inc. (0.00%), Aurinia Pharmaceuticals Inc. (7.74%), Theravance Biopharma, Inc. (7.26%), and Protagonist Therapeutics, Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. UroGen Pharma's stock is trading up $0.77 today. To short UroGen Pharma stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that UroGen Pharma will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is April, 15 2021.